Navigation Links
Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
Date:5/2/2011

NEW YORK, May 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC: GNBT) today announced that Mark Fletcher, CEO, will present at RetailInvestorConferences.com.

DATE: May 5th, 2011
TIME:  11:00 AM EDT
LINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

About RetailInvestorConferences.com

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Launches New Corporate Website
2. Generex Unveils Strategic Development Plan
3. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
4. Generex Provides Further Information for March 30 Press Conference & Investor Call to Discuss Managements Strategic Development Plan for Future Growth
5. Generex Schedules Press Conference & Investor Call for March 30th to Discuss Managements Strategic Development Plan for Future Growth
6. Generex Announces New Treatment IND Site for the USFDA Expanded Access Treatment IND Program for Generex Oral-lyn™ in the United States
7. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
8. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
9. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
10. Generex Announces Extension of Global Medical Direct Acquisition Closing Date
11. Generex Receives New Patent for Buccal Drug Delivery Platform Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Alzheimer Diagnostic Tests - Medical Devices ... Devices sector report , "Alzheimer Diagnostic Tests - ... of Alzheimer Diagnostic Tests currently in pipeline stage. ... pipeline products with comparative analysis of the products ... major players involved in the pipeline product development. ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG Technologies, ... PW Series Solvent Recycling Systems, specifically designed for ... integration with new and existing vapor degreasers, parts ... consistently-fresh solvent through continuous recycling and recovers 100% ... --> --> Precision parts manufacturers ...
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
Breaking Medicine Technology:
(Date:2/9/2016)... Cambridge, MA (PRWEB) , ... February 09, 2016 ... ... Institute (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for ... medical services covered in the report, Evaluation of the 2015 Fee Schedule ...
(Date:2/9/2016)... Fairfax, VA (PRWEB) , ... February 09, 2016 , ... ... Maryland. The family scheduled an appointment after they noticed their furnace not producing any ... a cracked heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has published ... have a basic understanding of the techniques they use so they can more ... them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... Rosa, California (PRWEB) , ... February 09, 2016 , ... ... rated one of the highest preliminary data vendors in the latest KLAS report, Population ... years, i2i has led the developing market for population health management (PHM). The ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Human Nutrition into the Food & Beverage and Dietary Supplement ... channel partner throughout Canada and USA geographies east of the Rocky Mountains since ...
Breaking Medicine News(10 mins):